Menu
FDA DECISION ·
Rybrevant Faspro
amivantamab and hyaluronidase-lpuj · Janssen Biotech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Subcutaneous monotherapy for adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) after progression on or following platinum chemotherapy and an anti-PD-(L)1 antibody. The use excludes HPV-associated oropharyngeal squamous cell carcinoma.
SUPPORTING DATA
Evidence behind the decision
- Study
- OrigAMI-4 was a multicenter, open-label study. The primary HNSCC efficacy group included 102 patients.
- Key result
- Independent review found a 42% overall response rate (95% CI, 32%–52%). Of responders, 56% maintained a response for at least six months.
- Safety to report
- FDA labeling flags administration reactions and hypersensitivity, ILD or pneumonitis, skin reactions and ocular toxicity.
- Evidence limits
- The efficacy group had no randomized comparator. Response and duration of response do not establish a comparative survival benefit.
LAMPGEN ANALYSIS
Why it matters
This adds an EGFR–MET bispecific option for a heavily treated head and neck cancer population. The activity reported in OrigAMI-4 gives a reason to follow the confirmatory work and the durability of response.
What research teams should watch
The label makes prior platinum and checkpoint therapy, progression timing and HPV-associated oropharyngeal status important source-document checks. Confirmatory teams also need consistent response assessment and toxicity escalation.
Clinical operations takeaway
Build the monitoring checklist around protocol-specific eligibility and source documentation for prior treatment. Give sites a named contact for resolving conflicting or incomplete records before eligibility review.
Evaluate protocol-specific oncology experiencePRIMARY RECORDS